A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC)

ID Number 14-0149

Principal Investigator(s)
Celina Ang

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to investigate if the study drug refametinib works and is safe in patients with liver cancer carrying a specific gene mutation (RAS mutation).  The study is considered research because the study drug refametinib is under development and has not been approved by the Food and Drug Administration (FDA) for the treatment of HCC or for sale yet.

Refametinib is an oral drug that may work by stopping the cell growth in a specific way in cancer cells.  It is thought from previous studies that refametinib may help in the treatment of your cancer.

Contact Information
(212) 824-7309

Recruiting Patients: No